← Back to Screener
Vistagen Therapeutics, Inc. Common Stock (VTGN)
Price$0.54
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-96.83%
Price vs S&P 500 (4W)-10.90%
VGM Score45.90
Market Capitalization$22.19M
All Metrics
Book Value / Share (Quarterly)$1.29
P/TBV (Annual)8.03x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-24.07%
Cash Flow / Share (Quarterly)$-1.53
Price vs S&P 500 (YTD)-25.99%
Net Profit Margin (TTM)-6634.91%
EPS (TTM)$-1.46
10-Day Avg Trading Volume0.63M
EPS Excl Extra (TTM)$-1.46
EPS (Annual)$-1.67
ROI (Annual)-73.05%
Net Profit Margin (5Y Avg)-4021.58%
Cash / Share (Quarterly)$1.56
Revenue Growth QoQ (YoY)29.49%
ROA (Last FY)-60.96%
Revenue Growth TTM (YoY)15.28%
EBITD / Share (TTM)$-1.51
ROE (5Y Avg)-136.34%
Operating Margin (TTM)-6882.36%
Cash Flow / Share (Annual)$-1.46
P/B Ratio0.44x
P/B Ratio (Quarterly)0.51x
Net Income / Employee (Annual)$-871,500
EV / Revenue (TTM)-30.81x
Net Interest Coverage (TTM)-2458.00x
ROA (TTM)-74.56%
EPS Incl Extra (Annual)$-1.67
Current Ratio (Annual)6.51x
Quick Ratio (Quarterly)4.57x
3-Month Avg Trading Volume0.83M
52-Week Price Return-77.05%
Revenue / Employee (TTM)$13,600
Tangible BV / Share (Quarterly)$2.97
P/S Ratio (Annual)45.66x
Asset Turnover (Annual)0.01x
52-Week High$5.14
Operating Margin (5Y Avg)-4278.00%
EPS Excl Extra (Annual)$-1.67
Tangible BV CAGR (5Y)11.80%
26-Week Price Return-88.90%
Quick Ratio (Annual)6.38x
13-Week Price Return-11.46%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.67x
Enterprise Value$-24.80M
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-13.70%
Revenue / Employee (Annual)$8,200
Pretax Margin (Annual)-10578.40%
Cash / Share (Annual)$2.78
3-Month Return Std Dev62.23%
Net Income / Employee (TTM)$-905,300
ROE (Last FY)-73.05%
Net Interest Coverage (Annual)-5.41x
EPS Basic Excl Extra (Annual)$-1.67
Receivables Turnover (TTM)4.00x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-1.46
ROI (TTM)-91.04%
P/S Ratio (TTM)27.57x
Pretax Margin (5Y Avg)-4021.05%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$1.65
Price vs S&P 500 (52W)-101.42%
Year-to-Date Return-17.83%
5-Day Price Return-16.00%
EPS Normalized (Annual)$-1.67
ROA (5Y Avg)-89.22%
Net Profit Margin (Annual)-10579.84%
Month-to-Date Return-13.67%
Cash Flow / Share (TTM)$-4.52
EBITD / Share (Annual)$-1.81
Operating Margin (Annual)-11517.08%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-135.54%
LT Debt / Equity (Quarterly)0.02x
EPS Basic Excl Extra (TTM)$-1.46
P/TBV (Quarterly)2.72x
P/B Ratio (Annual)1.03x
Pretax Margin (TTM)-6634.91%
Book Value / Share (Annual)$2.43
Price vs S&P 500 (13W)-19.71%
Beta0.41x
Revenue / Share (TTM)$0.02
ROE (TTM)-92.08%
52-Week Low$0.43
gGradeB
mGradeD
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
2.50
2.50
2.50
2.50
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VTGNVistagen Therapeutics, Inc. Common Stock | — | B | D | $0.54 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Vistagen Therapeutics is a biotechnology company developing novel therapies for psychiatric and neurological disorders using proprietary nose-to-brain delivery technology. The company's targeted approach leverages neurocircuitry insights to potentially create unique treatment pathways for conditions currently lacking effective options.